EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative analysis of common potency assays for assessing human TNF-alpha neutralising antibodies

Rithwik Pradeep, Alexander Zhdanov, Evin Allen

Analytical Biochemistry · 2026-02 · 709 · 116011

DOI: 10.1016/j.ab.2025.116011 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Analytical Biochemistry, 2026-02. Verfasst von Rithwik Pradeep und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University College Cork, Ireland. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Antibodies, Neutralizing, Antibodies, Monoclonal. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumour necrosis factor-alpha (TNF-α) plays a central role in inflammation and autoimmune pathology, making it a key therapeutic target. This study systematically evaluated the performance of monoclonal anti-human TNF-α antibodies derived from hybridoma cells-originally developed during early TNF research-using two widely adopted in vitro potency assays: a cytotoxicity-based assay in L929 fibroblasts and an NF-κB reporter assay in HEK293 Blue cells. Antibody performance was assessed in terms of neutralisation efficiency, signal reproducibility, and assay sensitivity. While both assays yielded comparable IC50 values (1.98 for L929 and 1.34 for HEK293 Blue), they differed in dynamic range, sensitivity, and biological relevance. The HEK293 Blue assay provided rapid, robust, and high-throughput-compatible detection of early TNF-α signalling events, with minimal background and superior reproducibility. In contrast, the L929 assay offered physiologically relevant insights into the later consequences of TNF-α signalling, such as apoptosis and metabolic disruption. ATP quantification using the CellTiter-Glo® assay proved to be a practical and sensitive method for viability assessment, though alternative metabolic and membrane integrity assays may complement interpretation. Overall, our findings highlight the complementary strengths of these assay platforms and support a dual-assay approach for comprehensive evaluation of anti-TNF-α antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor-alphaAntibodies, NeutralizingAntibodies, MonoclonalHumansHEK293 CellsAnimalsMiceNF-kappa B

Stichwörter der Autor:innen

Dual-assay approachNeutralising mAbsPotency assayTNF-α

Substanzen

Tumor Necrosis Factor-alphaAntibodies, NeutralizingAntibodies, MonoclonalNF-kappa B

Autor:innen und Institutionen

  • School of Pharmacy, University College Cork, Ireland.
  • School of Pharmacy, University College Cork, Ireland. Electronic address: a.zhdanov@ucc.ie.
  • School of Pharmacy, University College Cork, Ireland. Electronic address: EvinAllen@ucc.ie.

Zitieren

APA

Pradeep, R., Zhdanov, A., & Allen, E. (2026). Comparative analysis of common potency assays for assessing human TNF-alpha neutralising antibodies. Analytical Biochemistry, 709, 116011. https://doi.org/10.1016/j.ab.2025.116011

Vancouver

Pradeep R, Zhdanov A, Allen E. Comparative analysis of common potency assays for assessing human TNF-alpha neutralising antibodies. Analytical Biochemistry. 2026;709:116011. doi:10.1016/j.ab.2025.116011

BibTeX
@article{Pradeep2026,
  author = {Pradeep, Rithwik and Zhdanov, Alexander and Allen, Evin},
  title = {Comparative analysis of common potency assays for assessing human TNF-alpha neutralising antibodies},
  journal = {Analytical Biochemistry},
  year = {2026},
  volume = {709},
  pages = {116011},
  doi = {10.1016/j.ab.2025.116011}
}
Kostenlos starten →